Literature DB >> 1733625

Molecular heterogeneity of human IgA antibodies during an immune response.

M W Russell1, C Lue, A W van den Wall Bake, Z Moldoveanu, J Mestecky.   

Abstract

Human IgA occurs in multiple molecular forms (polymeric and monomeric) and two subclasses which show differential distribution between the mucosal and circulatory compartments of the immune system. However, the molecular form and subclass of specific IgA antibodies are influenced, especially during an immune response, by the type of antigen and duration of the response as well as by the route of exposure. These considerations question previously held notions that polymeric IgA and an increased representation of the IgA2 subclass among circulating antibodies or antibody-secreting cells signify their mucosal origin. Although the functional properties of different molecular forms and subclasses of IgA antibodies are incompletely understood, it appears that there is physiological benefit in the diversity of the IgA immune system.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733625      PMCID: PMC1554245          DOI: 10.1111/j.1365-2249.1992.tb06404.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  60 in total

1.  Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses.

Authors:  A Tarkowski; C Lue; Z Moldoveanu; H Kiyono; J R McGhee; J Mestecky
Journal:  J Immunol       Date:  1990-05-15       Impact factor: 5.422

2.  The origin of monomeric and polymeric forms of IgA in man.

Authors:  J Radl; H R Schuit; J Mestecky; W Hijmans
Journal:  Adv Exp Med Biol       Date:  1974       Impact factor: 2.622

3.  IgA subclasses in various secretions and in serum.

Authors:  D L Delacroix; C Dive; J C Rambaud; J P Vaerman
Journal:  Immunology       Date:  1982-10       Impact factor: 7.397

4.  Ontogeny of secretory immunity: levels of secretory IgA and natural antibodies in saliva.

Authors:  G R Burgio; A Lanzavecchia; A Plebani; S Jayakar; A G Ugazio
Journal:  Pediatr Res       Date:  1980-10       Impact factor: 3.756

5.  The IgA system in connection with local and systemic immunity.

Authors:  J F Heremans
Journal:  Adv Exp Med Biol       Date:  1974       Impact factor: 2.622

6.  Antibody responses in serum and nasal secretions according to age of recipient and method of administration of A2-Hong Kong-68 inactivated influenza virus vaccine.

Authors:  R V Fulk; D S Fedson; M A Huber; J R Fitzpatrick; J A Kasel
Journal:  J Immunol       Date:  1970-01       Impact factor: 5.422

7.  Estimation of polymeric IgA in human serum: an assay based on binding of radiolabeled human secretory component with applications in the study of IgA nephropathy, IgA monoclonal gammopathy, and liver disease.

Authors:  M M Newkirk; M H Klein; A Katz; M M Fisher; B J Underdown
Journal:  J Immunol       Date:  1983-03       Impact factor: 5.422

8.  Serum levels of IgA1 and IgA2 in children and in patients with IgA deficiency.

Authors:  M E Conley; A Arbeter; S D Douglas
Journal:  Mol Immunol       Date:  1983-09       Impact factor: 4.407

9.  Oligomeric immunoglobulin A antibody response to rubella virus infection.

Authors:  S Inouye; R Kono; Y Takeuchi
Journal:  J Clin Microbiol       Date:  1978-07       Impact factor: 5.948

10.  Tissue origins of human polymeric and monomeric IgA.

Authors:  W H Kutteh; S J Prince; J Mestecky
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

View more
  18 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Subclass distribution of natural salivary IgA antibodies against pneumococcal capsular polysaccharide of type 14 and pneumococcal surface adhesin A (PsaA) in children.

Authors:  B Simell; T Kilpi; H Käyhty
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

3.  Tumour-infiltrating lymphocytes in primary melanoma: functional consequences of differential IL-2 receptor expression.

Authors:  J C Becker; A Schwinn; R Dummer; G Burg; E B Bröcker
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

4.  Intestinal IgA: novel views on its function in the defence of the largest mucosal surface.

Authors:  J Mestecky; M W Russell; C O Elson
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

Review 5.  Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system.

Authors:  H Y Wu; M W Russell
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

6.  Human nasopharyngeal-associated lymphoreticular tissues. Functional analysis of subepithelial and intraepithelial B and T cells from adenoids and tonsils.

Authors:  P N Boyaka; P F Wright; M Marinaro; H Kiyono; J E Johnson; R A Gonzales; M R Ikizler; J A Werkhaven; R J Jackson; K Fujihashi; S Di Fabio; H F Staats; J R McGhee
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

7.  Subclass distribution of IgA antibodies in saliva and serum after immunization with Haemophilus influenzae type b conjugate vaccines.

Authors:  M Kauppi-Korkeila; L Saarinen; J Eskola; H Käyhty
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

8.  Increased IL-10 production by stimulated whole blood cultures in primary IgA nephropathy.

Authors:  J W De Fijter; M R Daha; W E Schroeijers; L A van Es; C Van Kooten
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

9.  Relationship of in vitro phagocytosis of serotype 14 Streptococcus pneumoniae to specific class and IgG subclass antibody levels in healthy adults.

Authors:  J E Lortan; A S Kaniuk; M A Monteil
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

Review 10.  Ankylosing spondylitis, IgA, and transforming growth factors.

Authors:  J R Archer
Journal:  Ann Rheum Dis       Date:  1995-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.